Citations

Showing 10 of 108094 citations.

A miraculous recovery: Bartonella henselae infection following a red ant bite
Agarwal, Anjali , Fritz, Ashley Virginia , Guru, Pramod K., Fritz, Ashley, Guru, Pramod

Mayo Clinic

BMJ Case Reports | May 4, 2018 | Volume: 2018 | Issue: No issue available | Pages: bcr-2017-222326

10.1136/bcr-2017-222326 | PMID 29728431 Get It

Infections caused by the Bartonella species are responsible for the human diseases collectively called ‘bartonellosis’. The clinically important human infections are mostly caused by the three species (eg, B. bacilliformis, B. quintana and B. henselae) of Bartonella out of the many progressively increasing identified species. Bartonella henselae transmitted by the arthropod vector, fleas, after cat bite is responsible for the rare multisystem cat scratch disease in humans. We present an extremely rare case of B. henselae contracted presumably through a red ant bite. The patient had a prolonged hospital stay for persistent encephalopathy due to delay in diagnosis and initiation of antimicrobial therapy. His hospital course was complicated by two episodes of pulseless electrical activity cardiac arrest related to pulmonary embolism. However, he recovered to his baseline status in the hospital with timely administration of systemic anticoagulation and antimicrobials. He was discharged home with no neurological deficits.
Treatment of Peripheral Nerve Injuries
Craig, Winchell McK.

Mayo Clinic

Military Medicine | May 4, 2018 | Volume: 103 | Issue: 1 | Pages: 1-8

10.1093/milmed/103.1.1 Get It

Subclinical Hypothyroidism in Women Planning Conception and During Pregnancy: Who Should Be Treated and How?
Maraka, Spyridoula , Ospina, Naykky Singh , O’Keeffe, Derek T. , Ospina, Naykky Singh , Singh Ospina, Naykky M, Maraka, Spyridoula , Mastorakos, George P. , Singh Ospina, Naykky

Mayo Clinic

Journal of the Endocrine Society | May 4, 2018 | Volume: 2 | Issue: 6 | Pages: 533-546

10.1210/js.2018-00090 | PMID 29850652 Get It

AbstractSubclinical hypothyroidism (SCH), a mild form of hypothyroidism defined as elevated TSH with normal free thyroxine levels, is a common diagnosis among women of reproductive age. In some, but not all, studies, it has been associated with infertility, an increased risk of adverse pregnancy and neonatal outcomes, and possibly with an increased risk of neurocognitive deficits in offspring. Despite well-established recommendations on treatment of overt hypothyroid pregnant women, a consensus has not yet been reached on whether to treat women with SCH. This review focuses on examining the evidence informing the clinical strategy for using levothyroxine (LT4) in women with SCH during pregnancy and those who are planning conception. A crucial first step is to accurately diagnose SCH using the appropriate population-based reference range. For pregnant women, if this is unavailable, the recommended TSH upper normal limit cutoff is 4.0 mIU/L. There is evidence supporting a decreased risk for pregnancy loss and preterm delivery for pregnant women with TSH > 4.0 mIU/L receiving LT4 therapy. LT4 treatment has been associated with better reproductive outcomes in women with SCH undergoing artificial reproductive techniques, but not in those who are attempting natural conception. Thyroid function tests need to be repeated throughout pregnancy to monitor LT4 therapy. In addition to potential harms, LT4 contributes to treatment burden. During a consultation, clinicians and patients should engage in a careful consideration of the current evidence in the context of the patients’ values and preferences to determine whether LT4 therapy initiation is the best next step.
Is Adjunctive Progesterone Effective in Reducing Seizure Frequency in Patients With Intractable Catamenial Epilepsy? A Critically Appraised Topic
Crepeau, Amy Z. , Hoerth, Matthew T., Butler, Kristina , Almader‐Douglas, Diana , Wingerchuk, Dean M. , O’Carroll, Cumara B. , Almader-Douglas, Diana, Valencia-Sánchez, Cristina

Mayo Clinic

The Neurologist | May 4, 2018 | Volume: 23 | Issue: 3 | Pages: 108-112

10.1097/nrl.0000000000000167 | PMID 29722747 Get It

Background: Catamenial epilepsy refers to cyclic seizure exacerbation in relation to the menstrual cycle. Three distinct patterns have been described: C1-perimenstrual, C2-periovulatory, and C3-inadequate luteal. There is experimental and clinical evidence that gonadal steroid hormones affect neuronal excitability with estrogens being mainly proconvulsant and progesterone anticonvulsant. If reproductive steroids have a role in seizure occurrence, they may also have a role in treatment. Objective: The objective of this study was to critically assess current evidence regarding the efficacy of progesterone as adjunctive therapy in women with intractable catamenial epilepsy. Methods: The objective was addressed through the development of a structured critically appraised topic. This included a clinical scenario with a clinical question, literature search strategy, critical appraisal, results, evidence summary, commentary, and bottom line conclusions. Participants included consultant and resident neurologists, medical librarian, and content experts in the fields of epilepsy and gynecology. Results: A randomized, placebo-controlled clinical trial was selected for critical appraisal. This trial compared the efficacy of adjunctive cyclic natural progesterone therapy versus placebo for seizures in women with intractable partial epilepsy, stratified by catamenial and noncatamenial status. There was no significant difference in proportions of responders between progesterone and placebo in the catamenial and noncatamenial strata. Prespecified secondary analysis showed that the level of perimenstrual seizure exacerbation is a significant predictor of the responder rate for progesterone therapy. Conclusions: Cyclic natural progesterone is not superior to placebo in reducing seizure frequency in women with intractable partial epilepsy. Posthoc findings suggest that progesterone may benefit a subset of women with perimenstrually exacerbated seizures.
Rheumatoid Meningitis
Parsons, Angela, Zuniga, Leslie A., Lyons, Mark , Aslam, Fawad , Goodman, Brent P., Aslam, Fawad , Zuniga, Leslie A., Hoxworth, Joseph M.

Mayo Clinic

The Neurologist | May 4, 2018 | Volume: 23 | Issue: 3 | Pages: 83-85

10.1097/nrl.0000000000000158 | PMID 29722740 Get It

Introduction: Rheumatoid meningitis (RM) is a rare complication of rheumatoid arthritis (RA) and has a high mortality rate. It can present as a first diagnosis of RA, in long-standing disease, or in active or well-controlled disease. Neurological manifestations vary widely. Case Report: A patient with a 30-year history of RA, well controlled with methotrexate therapy, presented with new-onset seizures. Magnetic resonance imaging showed leptomeningeal and pachymeningeal enhancement. A de novo workup resulted in diagnosis of RM. Conclusions: Cerebrospinal fluid findings for RM are nonspecific, typically lymphocytic pleocytosis; however, they can be neutrophilic, as in this case. Magnetic resonance imaging findings consist of leptomeningeal and pachymeningeal enhancement but can also involve the parenchyma. The diagnosis is typically confirmed with meningeal biopsy. Treatment involves high-dose corticosteroids or immunomodulatory therapy, or both. Long-term follow-up with radiologic surveillance typically ranges from improvement to resolution.
Locally Recurrent Rectal Cancer
Mishra, Nitin

Mayo Clinic

Diseases of the Colon & Rectum | May 3, 2018 | Volume: 61 | Issue: 6 | Pages: 651-654

10.1097/dcr.0000000000001111 | PMID 29722723 Get It

Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With Cancer
Bartlett, David J. , Childs, Daniel S. , Breitkopf, Carmen Radecki , Grudem, Megan E. , Mitchell, Jessica L. , Looker, Sherry, Ridgeway, Jennifer L. , Butterfield, Joseph H. , Weroha, S. John , Jatoi, Aminah , Looker, Sherry A, Lee, Jennifer L, Jatoi, Aminah , Childs, Daniel S , Ridgeway, Jennifer L , Lee, Jennifer L.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | May 3, 2018 | Volume: 35 | Issue: 11 | Pages: 1384-1389

10.1177/1049909118773995 | PMID 29724109 Get It

Objective: A growing number of cancer antineoplastic agents can cause life-threatening acute infusion reactions. Because previous studies have not studied these reactions from the perspective of patients, this study was undertaken with that objective in mind. Methods: Patients who had an acute infusion reaction were interviewed based on the Leventhal model. Once saturation of content was achieved, interviews were transcribed and analyzed with qualitative methodology. Results: Twenty-one patients were enrolled. Most were women (n = 15); the median age was 58 years, and paclitaxel was the most common inciting agent. Three themes emerged. First, these reactions are frightening; patients made remarks such as “I was just thinking oh my God, I am dying.” Second, prior education about these reactions seemed to mitigate this fear, “Basically everything the nurses told me potentially could happen, like happened. So, I was prepared.” Third, when health-care providers were prompt and attentive during the reaction, patients described less fear with future chemotherapy, “So no, I’m really not fearful about going in tomorrow because I know they’ll be there and they’ll be watching me.” Conclusion: These reactions evoke fear which can be mitigated with education prior to and with prompt responsiveness during the acute infusion reaction.
Primary vs Secondary Endosseous Implantation After Fibular Free Tissue Reconstruction of the Mandible for Osteoradionecrosis
Menapace, Deanna C., Abel, Kathryn M. Van , Jackson, Ryan S. , Moore, Eric J. , Van Abel, Kathryn M

Mayo Clinic

JAMA Facial Plastic Surgery | May 3, 2018 | Volume: 20 | Issue: 5 | Pages: 401-408

10.1001/jamafacial.2018.0263 | PMID 29801119 Get It

Importance The clinical and financial implications of the timing of dental rehabilitation after a fibula free tissue transfer (FFTT) for osteoradionecrosis (ORN) and osteonecrosis (ON) of the mandible have yet to be established. Objective To compare the outcomes of primary implantation vs secondary implantation after FFTT for ORN and ON of the mandible. Design, Setting, and Participants A retrospective review was conducted of 23 patients at a single tertiary academic referral center undergoing primary implantation or secondary implantation after FFTT for ORN and ON from January 1, 2006, to November 10, 2015. Interventions All patients underwent FFTT with primary implantation (n = 12) or secondary implantation (n = 11). Main Outcomes and Measures Outcomes of FFTT, dental implantation, implant use, diet, speech, and disease-free survival were reviewed. Fixed unit costs were estimated based on the mean cost analysis. Results Twenty-three patients (7 women and 16 men; mean [SD] age, 62.4 [8.2] years [range, 24-81 years]) met the inclusion criteria. Of these, 18 had ORN and 5 had ON. Dental implantation was performed at the time of FFTT for 12 patients and was performed secondarily for 11 patients. There were a mean of 5.2 implants per patient performed, for a total of 121 implants. There was 1 complete flap failure in the primary implantation group. Neither flap nor implant complications were affected by the timing of the implantation. Overall, the implant survival rate was 95% (55 of 58) in the primary implantation group and 98% (62 of 63) in the secondary implantation group. Time from FFTT to abutment placement (primary implantation, 19.6 weeks; secondary implantation, 61.0 weeks) was significantly shorter after primary implantation ( P < .001). There was no clinical difference in postoperative complications and implant outcomes for ORN vs ON. Improvement in speech and oral competence in the primary implantation group vs the secondary implantation group was not statistically significant, given an experiment-adjusted P = .001 set as significant (normal speech, 9 vs 3; P = .02; and normal oral competence, 9 vs 3; P = .02). Disease-free survival was 91% (20 of 22 patients) overall. Fixed unit (U) costs were 1.0 U for primary implantation and 1.24 U for secondary implantation. Conclusions and Relevance Patients undergoing primary implantation after FFTT for ORN and ON had a similar rate of complications compared with those undergoing secondary implantation. However, primary implantation allowed a faster return than secondary implantation to oral nutrition and prosthesis use. The fixed unit cost was reduced for those undergoing primary implantation. Although dental implantation was safe and effective in both groups, the decreased time to use and the decreased overall cost should prompt surgeons to consider primary implantation after FFTT for ORN and ON. Level of Evidence 3 .
Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al
Molenaar, Remco J. , Sidana, Surbhi , Kalaycio, Matt, Nazha, Aziz , Adelstein, David J. , Nasr, Christian , Maciejewski, Jaroslaw P. , Majhail, Navneet S. , Sekeres, Mikkael A. , Radivoyevitch, Tomas, Majhail, Navneed S, Mukherjee, Sudipto, Majhail, Navneet S , Sidana, Surbhi , Sekeres, Mikkael A , Radivoyevitch, Tomas , Gerds, Aaron T. , Carraway, Hetty E. , Mukherjee, Sudipto

Mayo Clinic

Journal of Clinical Oncology | May 3, 2018 | Volume: 36 | Issue: 18 | Pages: 1889-1892

10.1200/jco.2018.78.4074 | PMID 29723096 Get It

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Stein, Eytan M. , Garcia‐Manero, Guillermo , Rizzieri, David A. , Tibes, Raoul , Jongen-Lavrenic, Mojca, Altman, Jessica K. , Thomson, Blythe, Blakemore, Stephen J. , Daigle, Scott R., Waters, Nigel J. , Suttle, A. Benjamin, Clawson, Alicia, Pollock, Roy M. , Krivtsov, Andrei V. , Armstrong, Scott A. , DiMartino, Jorge, Hedrick, Eric, Löwenberg, Bob , Tallman, Martin S. , Löwenberg, Bob , Berdeja, Jesús G. , Savona, Michael R.

Mayo Clinic

Blood | May 3, 2018 | Volume: 131 | Issue: 24 | Pages: 2661-2669

10.1182/blood-2017-12-818948 | PMID 29724899 Get It

Key Points Pinometostat demonstrates first evidence of DOT1L target inhibition and clinical responses in a subset of MLL-r advanced leukemia patients. The observed safety profile of pinometostat shows potential for exploration of combination therapies in leukemia.